AMYLOIDOSIS
SWOG 9628 *
Phase II Study of Dexamethasone/Alpha Interferon in Amyloidosis
Location and Contact: The University Hospital Barrett Cancer Center
SWOG Office pager 513-230-2709
BONE METS
RTOG 97-14 *
Randomized Trial of Palliative Radiation Therapy for Osseous Metastases: A Study of Palliation of Symptoms and Quality of Life (Patients must be primary breast or prostate)
Location and Contact: The University Hospital Barrett Cancer Center
Alison 513-584-0436, pager 513-595-1588
BRAIN
RTOG 98-03
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Location and Contact: The University Hospital Barrett Cancer Center
Alison 513-584-0436, pager 513-595-1588
RTOG 98-13 TEMPORARILY CLOSED
A Phase I/III Randomized Study of Radiation Therapy and Temozolomide versus Radiation Therapy and BCNU versus Radiation Therapy and Temozolomide and BCNU for Anaplastic Astrocytoma
Locations and Contacts: Marla 513-585-0844, pager 513-577-0262 and The University Hospital Barrett Cancer Center
Alison 513-584-0436, pager 513-595-1588
BREAST
RTOG 99-15
Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast Cancer in Women with One to Three Positive Axillary Nodes, Phase III
Locations and Contacts: Marla 513-585-0844, pager 513-577-0262 and The University Hospital Barrett Cancer Center
Alison 513-584-0436, pager 513-595-1588
NAFTA
P.I. Elizabeth Shaughnessy, M.D.
North American Fareston Tamoxifen Adjuvant Trial
A Phase II Study of Tamoxifen vs. Toremifene as Adjuvant Therapy for Women with Carcinoma of the Breast
Location and Contact: The University Hospital Barrett Cancer Center
Susan 513-584-0207, pager 513-595-1664
NSABP B-30
A Three-Arm Randomized Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Taxotere (AC-T); Adriamycin and Taxotere (AT); and Adriamycin, Taxotere, and Cyclophosphamide (ATC) in Breast Cancer Patients with Positive Axillary Lymph Nodes
Locations and Contacts: Marla 513-585-0844, pager 513- 577-0262 and The University Hospital Barrett Cancer Center
Susan 513-584-0207, pager 513-595-1664
NSABP B-31
A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC-T) to that of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer Patients Who Have Tumors that Over-Express HER 2
Location and Contact: The University Hospital Barrett Cancer Center
Susan 513-584-0207, pager 513-595-1664
NSABP B-31.1
A Study to Determine the Correlation of Cardiac Function with Patient Characteristics and Blood Markers in Women Enrolled in B-31 at The University Hospital Barrett Cancer Center.
Location and Contact: The University Hospital Barrett Cancer Center
Susan 513-584-0207, pager 513-595-1664
NSABP B-32
A Randomized, Phase III Clinical Trial to Compare Sentinel Node Resection to Conventional Axillary Dissection in Clinically Node-Negative Breast Cancer Patients
Location and Contact: The University Hospital Barrett Cancer Center
Susan 513-584-0207, pager 513-595-1664
NSABP B-33
A Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of Exemestane in Clinical Stage T1-3, N0-1, M0 Postmenopausal Breast Cancer Patients Completing at Least 5 years of Tamoxifen Therapy
Locations and Contacts: Marla 513-585-0844, pager 513-577-0262 and The University Hospital Barrett Cancer Center,Susan 513-584-0207, pager 513-595-1664
NSABP B-34
A Clinical Trial Comparing Adjuvant Clodronate Therapy vs. Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy
Locations and Contacts: Marla 513-585-0844, pager 513-577-0262 and The University Hospital Barrett Cancer Center, Susan 513-584-0207, pager 513-595-1664
NSABP P-2
Study of Tamoxifen and Raloxifene (STAR) in Post-Menopausal Women for the Prevention of Breast Cancer
Locations and ContactsMarla 513-585-0844, pager 513-577-0262 and The University Hospital Barrett Cancer Center, Danyelle 513-584-0618
BCIRG 006
A Phase III Randomized Trial comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC®T) with Doxorubicin and Cyclophosphamide followed by Docetaxel and Trastuzumab (AC®TH) and with Docetaxel Platinum Salt and Trastuzumab (TCH) in the Treatment of Node Positive and High Risk Node Negative Adjuvant Patients with Operable Breast Cancer Containing the HER2NEU Alteration. Herceptin and Taxotere is provided.
Location and Contacts:Marla 513-585-0844, pager 513-577-0262
GASTROINTESTINAL
SWOG 9444 *
Gastrointestinal Tumor Repository Protocol, Ancillary
SWOG C9581 *
Phase III Randomized Study of Adjuvant Immunotherapy with Monoclonal Antibody 17-1A vs. No Adjuvant Therapy Following Resection for Stage II Modified Astler-Coller B2 Adenocarcinoma of the Colon
Location and Contact: The University Hospital Barrett Cancer Center,
SWOG Office pager 513-230-2709
NSABP C-07 *
A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin with 5-FU Plus LV for the Treatment of Patients with Stages II and III Carcinoma of the Colon
Locations and Contacts: Marla 513-585-0844, pager 513-577-0262 and The University Hospital Barrett Cancer Center Susan 513-584-0207, pager 513-595-1664
COL 2001 P.I. *
John Winklemann, M.D.
Protocol AVF2192g: A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab), A Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, in Combination with 5-Fluorouracil and Leucovorin Chemotherapy in Subjects with Metastatic Colorectal Cancer Who Are Not Optimal Candidates for First-Line CPT-11
Location and Contact: The University Hospital Barrett Cancer Center,
Kim 513-584-6403, pager 513-230-2415
COL 2002 P.I. *
John Winklemann, M.D.
Protocol AVF2107g: A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination with Standard Chemotherapy in Subject with Metastatic Colorectal Cancer
Location and Contact: The University Hospital Barrett Cancer Center
Kim 513-584-6403, pager 513-230-2415
RTOG 98-11 *
A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin and Radiotherapy in Carcinoma of the Anal Canal
Location and Contact: The University Hospital Barrett Cancer Center
Alison 513-584-0436, pager 513-595-1588
SWOG R9704 *
A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma
Location and Contact: The University Hospital Barrett Cancer Center
SWOG Office pager 513-230-2709
ESO 9801 P.I. *
John Winklemann, M.D.
A Phase II Evaluating the Role of Neoadjuvant Sequential Chemotherapy (Gemcitabine and Paclitaxel) and Chemoradiation (Cisplatin and 5-Fluorouracil) Followed by Surgery, in Resectable Esophageal and Proximal Gastric Carcinomas
Location and Contact: The University Hospital Barrett Cancer Center
SWOG Office pager 513-230-2709
RTOG 99-04 *
A Phase II Trial of Preoperative Chemotherapy and Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Stomach
Location and Contact: The University Hospital Barrett Cancer Center
Alison 513-584-0436, pager 513-595-1588
SWOG S9915
A Phase II Study of PN401, 5-FU, and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach
Location and Contact: The University Hospital Barrett Cancer Center
SWOG Office pager 513-230-2709
PC4e
A Prospective, Randomized, Controlled, Double Blind, Multi-national, Multi-center Study of G17DT Immunogen in Combination with Gemcitabine versus G17DT Placebo in Combination with Gemcitabine in Previously Untreated Subjects with Locally Advanced (Nonresectable Stage II and III), Recurrent Disease Following Primary Resection, or Metastatic (Stage IV) Adenocarcinoma of the Pancreas. G17DT/Placebo is provided by Aphton.
Locations and Contacts: Marla 513-585-0844, pager 513-577-0262
GENITOURINARY
SWOG 9916 *
Docetaxel and Estramustine Versus Mitroxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer, Phase III
Location and Contact: The University Hospital Barrett Cancer Center
SWOG Office pager 513-230-2709
RTOG 96-01 *
A Phase III Trial of Radiation Therapy With or Without Casodex in Patients with PSA Elevation Following Radical Prostatectomy for pT3N0 Carcinoma of the Prostate
Locations and Contacts: Marla 513-585-0844, pager 513-577-0262 and The University Hospital Barrett Cancer Center
Alison 513-584-0436, pager 513-595-1588
RTOG 99-02 TEMPORARILY CLOSED
A phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) versus AS and RT Followed by Chemotherapy with Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Location and Contacts: Marla 513-585-0844, pager 513-577-0262
GYNECOLOGICAL
RTOG 99-05
A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Taxol Chemotherapy Following TAH/BSO for Patients with Endometrial Cancer
Location and Contact: The University Hospital Barrett Cancer Center
Alison 513-584-0436, pager 513-595-1588
GIOV-001
OVARIAN Actimmune® (Interferon gamma-1b) in combination with carboplatin/paclitaxel for first line therapy of epithelial ovarian or primary peritoneal carcinoma, FIGO STAGE III or IV dz. (< 1 cm residual dz) Ecog 0-2, no prior BRM x 5 yrs, < 12 wks after initial surgery. Actimmune® Provided by InterMune.
Location and Contacts: Marla 513-585-0844, pager 513-577-0262
HEAD AND NECK
SWOG 8855
Prognostic Value of Cytometry Measurements of Cellular DNA Parameters in Head and Neck Cancer Patients, Ancillary
Location and Contact: The University Hospital Barrett Cancer Center
SWOG Office pager 513-230-2709
RTOG 99-01
A Phase III Study to Test the Efficacy and Safety of GM-CSF to Reduce the Severity and Duration of Mucosal Injury and Pain (Mucositis) Associated with Curative Radiation Therapy in Head and Neck Cancer Patients
Locations and Contacts: Marla 513-585-0844, pager 513-577-0262 and The University Hospital Barrett Cancer Center
Alison 513-584-0436, pager 513-595-1588
RTOG 99-03 *
A Randomized Phase III Trial to Assess the Effect of Erythropoietin on Local-Regional Control in Anemic Patients Treated with Radiotherapy for Carcinoma of the Head and Neck
Location and Contact: The University Hospital Barrett Cancer Center
Alison 513-584-0436, pager 513-595-1588
RTOG 99-11 *
A Phase II Study of Paclitaxel and Cisplatin in Combination with Split Course Concomitant Hyperfractionated Re-Irradiation in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck
Location and Contact: The University Hospital Barrett Cancer Center
Alison 513-584-0436, pager 513-595-1588
LEUKEMIA
SWOG 9910 *
Leukemia Centralized Reference Laboratories and Tissue Repositories- Consent to Perform Cellular and Molecular Studies in Leukemia Patients
Location and Contact: The University Hospital Barrett Cancer Center
SWOG Office pager 513-230-2709
LUNG
SMOKERS Win By Quitting: A Smoking Cessation Clinic
Location and Contact: The University Hospital Barrett Cancer Center
Brandon 513-584-3183, pager 513-691-0893
SCREENING The Lung Cancer Screening Project for Those at High Risk Using Spiral CT
Location and Contact: The University Hospital Barrett Cancer Center
Brandon 513-584-3183, pager 513-691-0893
LUN 2007
Lung Cancer Registry (all stages of lung cancer)
Location and Contact: The University Hospital Barrett Cancer Center
Brandon 513-584-3183, pager 513-691-0893
ACOSOG Z0030
Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy during Pulmonary Resection in the Patient with N0 or N1 (less than hilar) Non-Small Cell Carcinoma
Location and Contact: The University Hospital Barrett Cancer Center
Kim 513-584-6403, pager 513-230-2415
ACOSOG Z0040
A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient with Resectable Non-Small Cell Lung Carcinoma
Location and Contact: The University Hospital Barrett Cancer Center
Kim 513-584-6403, pager 513-230-2415
SWOG E5597 *
Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer
Location and Contact: The University Hospital Barrett Cancer Center
SWOG Office pager 513-230-2709
SWOG 9900 *
A Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Paclitaxel/Carboplatin in Clinical Stage IB (T2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer
Location and Contact: The University Hospital Barrett Cancer Center
SWOG Office pager 513-230-2709
LUN 2006 *
P.I., Abdul Jazieh, M.D.
Phase I/II Clinical Trial of Concurrent Paclitaxel, Carboplatin and External Beam Chest Irradiation with Glutamine in Patients with Locally Advanced Non-Small Cell Lung Cancer
Location and Contact: The University Hospital Barrett Cancer Center
Brandon 513-584-3183, pager 513-691-0893
LUN 2004 *
P.I., Abdul Jazieh, M.D.
Evaluation of the Efficacy of Prolonged Administration of Temozolomide in the Treatment of Advanced Non-Small Cell Lung Cancer
Location and Contact: The University Hospital Barrett Cancer Center
Brandon 513-584-3183, pager 513-691-0893
LUN 2008
P.I., Abdul Jazieh, M.D.
Phase II, Clinical Trial of Thalidomide, Irinotecan, and Gemcitabine in Advanced Non-Small Cell Lung Cancer
Location and Contact: The University Hospital Barrett Cancer Center
Brandon 513-584-3183, pager 513-691-0893
SWOG 0004
A Phase I Study of Tirapazamine/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
Location and Contact: The University Hospital Barrett Cancer Center
SWOG Office pager 513-230-2709
LUN 2005 *
P.I., Abdul Jazieh, M.D.
Evaluation of the Efficacy of Prolonged Administration of Temozolomide in the Treatment of Extensive Small Cell Lung Cancer
Location and Contact: The University Hospital Barrett Cancer Center
Brandon 513-584-3183, pager 513-691-0893
LYMPHOMA
SWOG 8947
Central Lymphoma Serum Repository Protocol
*SWOG E2496
A Randomized Phase III Trial ABVD Versus Stanford V +/- Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease with 0-2 Risk Factors
Location and Contact: The University Hospital Barrett Cancer Center
SWOG Office pager 513-230-2709
SWOG 9438
Total Body Irradiation, Etoposide, Cyclophosphamide & Autologous Peripheral Blood Stem Cell Transplantation followed by Stem Cell Transplantation followed by Randomization to Therapy with Interleukin-2 vs. Observation for Patients with Non-Hodgkin's Lymphoma, A BMT Study
Location and Contact: The University Hospital Barrett Cancer Center
SWOG Office pager 513-230-2709
MELANOMA
ACOSOG Z0020
P.I., Jeffrey Sussman, M.D.
Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion and Melphalan With or Without Tumor Necrosis Factor in the Patient with Localized, Advanced, Extremity Melanoma
Location and Contact: The University Hospital Barrett Cancer Center
Susan 513-584-0207, pager 513-595-1664
SWOG E3695 *
A Phase III Trial of Concurrent Biochemotherapy with Cisplatin, Vinblastine, Dacarbazine, IL-2 and Interferon vs. Cisplatin, Vinblastine, Dacarbazine Alone in Patients with Metastatic Malignant Melanoma
Location and Contact: The University Hospital Barrett Cancer Center
SWOG Office pager 513-230-2709
SWOG 0008 *
Phase III Trial of High Dose Interferon Alpha-2b versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients with High Risk Melanoma
Location and Contact: The University Hospital Barrett Cancer Center
SWOG Office pager 513-230-2709
SUNBELT
P.I., Jeffrey Sussman, M.D.
A Multicenter Trial of Adjuvant Interferon Alfa 2B for Melanoma Patients with Early Lymph Node Metastasis Detected by Lymphatic Mapping and Sentinel Lymph Node Biopsy
Location and Contact: The University Hospital Barrett Cancer Center
Susan 513-584-0207, pager 513-595-1664 |